Top Biotech & Life Sciences Investors 2026

Invest globally in biopharmaceutical, medical device, diagnostic, and life science tools companies driving medical innovation for patients with unmet medical needs, applying rigorous, science-first diligence across inflection capital, growth capital, fallen angels, and larger PE collaborations/new company formation.

A global healthcare specialist deploying a multi-strategy platform (venture, private equity, public equity) around an Ecosystem Approach that connects 460+ portfolio companies and industry operators to originate and support deals across the healthcare value chain.

Catalio invests in category-defining healthcare companies across drugs, devices, diagnostics, data, and AI-enabled digital tools that bend the cost curve and redefine patient care, drawing on a network of 45+ scientist-entrepreneur Venture Partners for proprietary deal flow and scientific diligence.

Pfizer Ventures invests in areas of current and future strategic interest to Pfizer, backing transformative therapeutics in Oncology, Inflammation & Immunology, Cardiovascular, Metabolic/Obesity, and Vaccines, plus platform companies with diversified pipelines aligned to those areas.

Co-found and build breakthrough life sciences and deep-science companies with university researchers. Follow science to create revolutionary technologies that prevent, detect, and cure disease. Patient capital from concept stage through commercialization.

Decheng Capital provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence, capitalizing on the rapid growth of the healthcare industry and breakthroughs in life science research. A cross-border US-China network and dealflow advantage differentiates the firm.

Mérieux Equity Partners is a leading European healthcare-specialized investment firm, powered by Institut Mérieux, investing in companies with ambitious growth projects and products or services transformative for health. It supports development and growth from business launch to large-scale deployment through capital investment and tailor-made, sector-expert support.

Medtech innovation is one of the most powerful ways to both improve the quality of healthcare and reduce its cost. We partner with entrepreneurs building breakthrough medical technology across medical devices, diagnostics, life science tools, and data-science-enabled healthcare solutions, pairing capital with deep technical, clinical, and commercial expertise via Vensana Innovation.

Breakthrough science merged with operational rigor creates transformational opportunities in life sciences. We identify emerging fields at the intersection of science and unmet medical need, then actively shape company formation working with scientific founders and expert advisors to design strategy from inception.

Leaps by Bayer invests in teams pursuing fundamental breakthroughs in life science targeting ten huge challenges across health and agriculture — from curing genetic diseases and cancer to transforming sustainable farming. They seek paradigm-shifting biotechnologies that move medicine from treating symptoms to curing or preventing diseases, and transform agriculture to nourish a growing population while restoring the planet.

Transforming disruptive European academic research into innovative therapeutics and diagnostics for severe diseases with high unmet medical needs. Operates as a venture builder, co-founding companies ex-nihilo from scientific discoveries and backing established venture-stage biotechs.

Fostering breakthrough innovation in healthcare: Asabys invests in highly innovative and transformative biopharma, medtech, and digital health technologies, partnering hands-on with portfolio companies from inception to growth to translate disruptive science into patient impact.

Healthcare is one of the most compelling long-term investment opportunities globally, driven by aging demographics, rising healthcare spending, and continuous scientific innovation. We invest across the entire healthcare value chain to drive innovation and address unmet medical needs.

Invest to develop commercially successful innovative life science companies in pharmaceuticals, diagnostics, and digital health, operating with independent decision-making separate from Roche R&D, often co-investing alongside Roche/Genentech R&D collaborations.

Data science-driven approach to investing in companies that leverage biology and big data to transform healthcare, marrying tech and biotech to personalize medicine and accelerate innovation across the full company lifecycle from incubation to IPO and beyond.

GHI partners with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. The fund is therapeutic-and-brand-agnostic, investing across drug discovery & clinical development, manufacturing/supply chain & IT, access to medicine & patient support, and real-world evidence generation.

WRF Capital funds the commercialization of cutting-edge technology spinouts from Washington research institutions, often as the first institutional money in, using licensing revenue earned from UW technology to seed the next generation of local founders.

Fund and build next-generation life sciences companies solving important healthcare needs through cutting-edge breakthroughs in medicine and science. Partner closely with management teams to maximize returns across all portfolio companies through hands-on operational support, strategic guidance, and access to networks of experienced life science leaders.

Enable breakthroughs in antimicrobials by investing in clinical- and late-stage biotech companies developing therapeutics for WHO/CDC priority pathogens, bridging the funding gap that traditional VC has abandoned in antibiotics, with a goal of helping launch 2-4 new antimicrobials by 2030.

M Ventures backs transformational, technical founders across biotech and deep tech whose innovations can generate strong financial returns while plausibly intersecting with Merck's mid-to-long-term business interests. It takes an active, hands-on role, frequently co-leading rounds and brokering partnerships between portfolio companies and Merck or other industry players.

We search the emerging technology landscape for visionary entrepreneurs and innovative new ideas with the potential to deliver better patient health outcomes through advances in biology, medicine, and information. Santé leads entry rounds for innovative healthcare and life science companies well-positioned to improve patient outcomes.

Empowering Pharmaceutical Innovation, Safeguarding Human Health. Hankang Capital partners with top scientists and entrepreneurs in China to develop breakthrough therapies for major diseases, rooted in China with a global vision.

Technology and biology are converging to create the next generation of transformative companies. The digitization of life sciences—driven by exponential growth in biological data and advances in AI/ML—is enabling a new class of platform companies that will dominate the industry. Tomorrow's biotech will be built by teams of three: a biologist, a chemist, and a computer scientist.

Translating groundbreaking science into life-changing medicines through seed-led investment model emphasizing science-first, patient-centric, collaborative approach. Play the long game with urgency - combining patient discipline with speed to market.

Venture capital can do more than fund companies—it can create them from the ground up. Newpath Partners specializes in building biotechnology companies in partnership with leading academic scientists, focusing on breakthrough biology platforms in gene editing, regenerative medicine, and transformational therapeutics that address the greatest unmet medical needs.

Transform technological breakthroughs from Belgian universities, research institutes, and hospitals into sustainable businesses, backing both university/knowledge-partner spin-offs and independent start-ups with structured R&D collaborations.

Enable and accelerate the development and commercialization of market-shaping innovations that are between, beyond, or disruptive to current ZEISS Strategic Business Units. As a strategic Deep Tech investor, ZEISS Ventures targets pre-Series A / Series A start-ups with interlinked software and hardware systems and scalable B2B business models, concentrated in MedTech & Life Sciences, Photonics & Optics/Semiconductor, and Industrial Technology.

Deep clinical and scientific diligence in healthcare, deployed across public equities, growth/PIPE financings, and later-stage private rounds within a single crossover platform.

Longevity is a completely new industry within biotech requiring founders who can think differently. Mission-oriented, founder-led companies with unconventional backgrounds will prove most effective at bringing the first longevity drugs to market and extending human healthy lifespan. The field is at a critical inflection point where we will either breakthrough to mainstream or get silo'd in a funding winter.

Complex health problems require multidisciplinary teams combining deep technical, financial, and domain expertise. We invest in breakthrough science and technology-enabled solutions across human and animal health.

Fund visionary entrepreneurs solving humanity's most intractable, long-horizon science and engineering problems, taking a poly-solution approach that backs many independent bets on the same hard problem (especially Alzheimer's disease and depression) rather than a single best guess, judged on both societal and financial impact.

Investing with purpose, investing in progress: back startups strategically aligned to dsm-firmenich's Perfumery & Beauty, Taste Texture & Health, and Health Nutrition & Care business units, pairing capital with the parent company's scientific, technological and commercial resources.

Backing 'Venture Scientists' — PhD-trained technical founders applying rigorous scientific methodology to build transformative companies from fundamental research. Focus on deep tech and life sciences areas that address climate change, resource scarcity, and healthcare accessibility. Targets university spinouts and science-led startups in areas that are difficult to diligence for generalist investors.

Clave partners with universities, hospitals, and research centers to turn Spanish scientific research into investable companies (tech transfer) in health, food, and industrial technology, while also backing established industrial SMEs and renewable energy infrastructure.

Physics is the basis for industry transformations in energy, transportation, finance, healthcare, and aerospace. Quantonation invests in breakthrough technologies emerging from advances in physics and computing -- quantum computing, quantum sensing, quantum networks, deep physics, and advanced materials -- from pre-seed through Series A, with selective Series B follow-on.

Funding the next generation of contrarian founders building breakthrough longevity biotech companies. We invest in the transition from sickcare to healthcare by extending healthy lifespan and preventing age-related disease.

Evidence-based, multi-stage investing in healthcare, life sciences, and planetary health. RA Capital pairs deep scientific diligence (via proprietary TechAtlas platform) with flexible multi-stage capital—from NewCo incubation through public markets—to support breakthrough companies from inception through commercialization. The firm's core belief is that rigorous landscape research and scientific depth consistently identify winners before the market recognizes them.

The era of transformational science is here. Life sciences and industrial markets are being reshaped by founders who move fast and build at the intersection of biology, chemistry, computation, and AI. This is a step-change in how science becomes solutions. We back bold founders who go beyond solving technical problems to redefine entire markets.

Advanced therapies—cell and gene therapy, RNA-based therapy, targeted therapies (ADCs), radiopharmaceuticals, and the microbiome—represent the next frontier in medicine. 4BIO partners with visionary biotech founders and serves as a therapeutic navigator, guiding breakthrough technologies from scientific innovation to life-changing therapies for patients with high unmet medical needs.

Funds founders elevating brain and mental health through neuroscience, frontier technologies, psychedelic medicine, precision neuroscience, neurotechnology, AI-enabled diagnosis and treatment, novel CNS therapeutics, digital health, and related modalities.

Invests in transformative early-stage MedTech companies addressing large unmet global healthcare needs, backing innovative therapeutic devices, diagnostics, and digital health solutions with the potential to become the new standard of care.

Data-driven technologies that transform the cancer care journey end-to-end: from early detection and precision diagnostics, to care navigation and survivorship, and the non-drug infrastructure that makes treatment work in the real world. The $210B+ US oncology market is fragmented and evidence-based care is chronically underdelivered — technology can close this gap while reducing costs.

Digital health has evolved from hype into infrastructure. CRB backs European health technology companies that have already passed clinical or regulatory validation and are ready to scale commercially, providing hands-on operational, industrial, and technological support alongside capital.

Create first-in-category bioplatform companies through scientific innovation and systematic entrepreneurship. Combine institutional scale with pioneer creativity to build breakthrough life sciences companies.

We believe the greatest advancements of our lifetime will be the result of reprogramming chemistry and biology using creative technology platforms. We invest at the frontier of science, supporting founders re-architecting the world at a molecular level.

Chalmers Ventures transforms breakthrough Chalmers University research into successful, impact-driven global companies, blending venture creation with venture investing under one roof.

Seizing the North of England's innovation opportunity by investing in science and technology startups with strong intellectual property solving global problems. Partners with the four Northern Arc universities (Leeds, Manchester, Sheffield, Liverpool) and the broader North of England ecosystem. Philosophy: profit with purpose — backing visionary founders with exceptional teams, breakthrough technology, and business models that deliver both financial returns and societal impact.

Back exceptional inventors building their own enduring businesses in life sciences. Founders who design the initial conditions of a company have superior odds of creating transformative value.

Frontier technology will underpin the next generation of globally significant companies. We back IP-rich, deep tech founders advancing intelligence, reinventing energy, accelerating computation, decoding biology, and building resilience — categories where traditional venture playbooks don't apply.

Seventure Partners identifies and backs innovative European companies in Life Sciences and Digital Technologies at all stages from seed to pre-IPO, serving as the lead investor and active board-level partner. The firm is a global pioneer in microbiome investing and has built a 25+ year track record of 150+ exits and 30 IPOs. Institutional backing from Natixis Investment Managers/Groupe BPCE provides unique co-investment and network access.

Healthcare's largest markets are ripe for disruption through software-first solutions. We back companies advancing care delivery through new technologies and care models, and software-first techbio platforms that transform drug discovery and therapeutic development.

Deep health emerges at the convergence of advances in biology, chemistry, AI/ML, robotics, and clinical medicine. We back visionary founders addressing root causes of chronic disease across three domains: biology within us (biotech platforms), environment around us (environmental/chemical health), and systems that care for us (healthcare delivery innovation).

Investing in healthcare data companies tackling the biggest problems in cancer care — from early detection to patient navigation to data access and AI-powered treatment optimization. The U.S. oncology system is fragmented, expensive, and filled with barriers to evidence-based care. We fund the technologies that fix this.

Investing in technological innovation to drive value creation with social impact, combining a VC lens on growth potential and industry trends with a growth investor's risk discipline. Sources opportunities in healthcare, AI & technology, consumer, and enterprise solutions, with a strong bias toward scientist-entrepreneur-led hard tech.

Backing founders transforming biology into an engineering discipline. We invest in the infrastructure stack of biology—synthetic DNA, cloud labs, automated experiments, computational drug design, and AI-for-biology—enabling science as a software problem at scale. We partner with technical founders who apply engineering rigor to biological challenges.

Founders backed by entrepreneurs. ZAKA bridges North American and CEE startup ecosystems, investing pre-seed to seed in Health & Biotech and Industrial Tech. The firm deploys institutional capital while leveraging operator networks to help European founders scale globally.

CincyTech partners with innovative founders solving the world's most complex challenges across life sciences, digital health, and technology-enabled markets, providing early capital and hands-on support to help ideas become venture-worthy companies, primarily across Southwest Ohio and the Midwest.

We focus on best-in-class commercial-stage healthcare companies that leverage technology to address the industry's most pressing issues, using our unique access to Providence and other strategic LPs to drive adoption.

Talented early-stage biotech founders need patient capital and experienced mentorship to navigate the intersection of genomics and data science. We provide both financial support and hands-on operational guidance from day one.

Deep tech unlocks new and ground-breaking pathways to solve fundamental societal challenges. We back technical founders with unique, defendable IP addressing large markets, providing hands-on, long-term capital across the full company lifecycle.

Originator of China's "hard tech" (硬科技) investment category: back deep, long-R&D-cycle science and engineering breakthroughs out of the Chinese Academy of Sciences network and top universities, from lab/PI stage through IPO, combining capital with an incubation platform and post-investment services.

Apply revolutionary biotechnology to replace industrial inputs with biology-based alternatives, transforming how the world manufactures chemicals, materials, foods, and medicines. Synthetic biology is a $25T opportunity spanning industrial inputs, food & agriculture, pharmaceuticals, and specialized applications.

Civilization Ventures backs exceptional scientific founders—particularly PhDs and postdocs from elite institutions—building essential innovations in health tech and biology. We believe the best breakthroughs come from disruptive science combined with founder determination. We provide 'mentor capital': not just capital, but active operational guidance, scientific rigor, and access to our network of Fellows, Advisors, and portfolio founders.

Dentistry is in the midst of a technology revolution driven by DSO consolidation and workforce/margin pressure. DIA is uniquely positioned to fund and network the most promising early-stage dental technology companies, leveraging a bench of DSO CEOs and dental leaders with access to 10,000+ US dental offices.

Investing in great people using breakthrough science and advanced engineering to create transformative impact across the future of food, health, and the environment. Long-term, active partner providing capital, expertise, and networks rather than passive investment.

We believe in the transformative power of individuals to drive systemic change and shape a more sustainable future. We champion visionary pre-seed/seed founders addressing humanity's most critical challenges over the next 30 years, regardless of sector or geography.

Sarsia invests in technologies that can improve quality of life, society, and reduce negative impact on nature, connecting scientific solutions with competent capital across life sciences and technology/energy/sustainability.

The breakthrough is the beginning. Partner with founders commercializing scientific and technological breakthroughs in biological platforms and applied robotics, helping them solve operational challenges to build durable, generational companies.

Tesi (Finnish Industry Investment Ltd) is a state-owned investment company that helps Finland's most promising companies grow bigger. Tesi invests on market terms as a minority co-investor alongside private capital in Finnish startups, scale-ups, and industrial projects, as well as in VC and PE funds. Its mandate is both financial returns and economic impact — driving growth, jobs, and renewal in the Finnish economy.

We back founders using technology to solve the world's biggest problems. We believe capitalism can be a force for good when companies are built to be both massively profitable AND create positive impact. The best entrepreneurs are determined, passionate, smart, creative, and can inspire thousands of talented people.

Back founders with deep, first-hand domain expertise in specific industry verticals — those who have 'lived' the problem they are solving. Vertical-first software delivers faster time-to-value and stronger retention versus horizontal tools requiring heavy customization.

We invest at the intersection of frontier technology - where breakthroughs in AI, bioengineering, and compute unlock bold solutions to the world's toughest challenges, anchored by pillars of Resilience and Security, Health and Wellbeing, and Building Inclusive Ecosystems.

We invest in transformative frontier science and technology that most VCs avoid. Our focus is on biotech, deep tech, psychedelics, brain-computer interfaces, life extension, and infrastructure bets in undercapitalized global markets. We believe the biggest winners in biotech are companies producing quality-adjusted life years (QALYs).

Synthetic biology and life sciences are engineering disciplines. The world's greatest challenges in human and planetary health will be solved by scientists and engineers using biology as a tool. We fund the earliest-stage founders with breakthrough ideas and provide wet lab infrastructure, capital, and long-term partnership.

HTGF backs ambitious tech founders at pre-seed and seed stage to build international market leaders. As Europe's most active early-stage investor and a public-private multi-stage platform, it invests across Industrial/Climate/Deep Tech, Life Sciences/Chemistry, and Digital Tech with a mandatory German nexus. HTGF combines capital, deep technical expertise, and a vast network spanning German industry, science institutions, and the European VC ecosystem. The fund also supports companies through growth rounds via its Opportunity Fund (up to 30M EUR per company).

Redalpine backs companies at the convergence of software and science — where rigorous engineering meets scientific breakthroughs. Half the team are scientists, half are operators, enabling them to engage deeply with highly technical founders and support them hands-on from day one through to exit. Primary focus areas: frontier science and biotech, digital health, AI and automation, fintech, synthetic biology, and climate tech.

DSC invests in paradigm-leading innovative entrepreneurs. The firm is strongest at early stage but open to all stages for teams with exceptional capability. Known for pioneering deep tech investments (AI, semiconductors, biotech) before they became mainstream, and for identifying unicorns years before public market recognition.

Solving the world's biggest challenges by supporting the world's best entrepreneurs in food and agriculture. Focus on sustainable, scalable solutions to global food security through innovation in alternative proteins, ingredients, and food technology.

Back innovative healthcare companies that drive better outcomes and superior value for patients, while leveraging the Blue Cross Blue Shield network's 115 million covered lives to help portfolio companies commercialize and land Blue Plan contracts.

More than 80% of UK venture capital is concentrated in London and the South East. PXN backs high-growth founders in the North of England, Scotland, and Northern Ireland with capital (£200K-£8M) plus hands-on, "more than money" operational support.

Growth capital for the next AgriFood system — backing founders reshaping how the world eats, lives, and sustains itself, with active board involvement and operator-level support.

Backing wildly ambitious founders using breakthrough technology (AI, data science, neuroscience, biotech) to build multi-billion-dollar companies that improve human health/wellness and planetary health/infrastructure.

Science-driven venture capital focused on breakthrough healthcare innovations. Deep scientific rigor in diligence with mechanism-of-action understanding, proof-of-concept validation, and extensive KOL/clinician engagement. Backed by Zambon Group pharmaceutical expertise.

Backs bold founders in technology and healthcare building companies that will define the future of their industries. Two practice areas: Enterprise/AI (AI infrastructure, frontier systems, cybersecurity, defense, fintech, developer tools) and Healthcare/Life Sciences (digital health, therapeutics, genomics, health system modernization). Deep partnership model, long-term patient capital approach across market cycles since 1969.

Canaan invests in visionaries with transformative ideas across a 60/40 technology-to-healthcare split. The firm seeks early-stage companies with authentic founder passion, clear problem-solving value, and the potential to improve lives. Canaan runs a transparent, debate-driven partnership with deep operational expertise in healthcare regulation, biotech fundraising, and enterprise scaling.

Advancing healthcare through investment, information, and philanthropy - investing across the capital structure and company lifecycle in therapeutics, medical devices, healthcare services, diagnostics, and digital health, with an internal R&D engine (3DC) that originates and incubates companies directly.

Invest in century-defining technologies and companies. Focus on infrastructure-oriented, cross-vertical applied AI for physical-world and life-science problems, with deep healthcare systems expertise. Transform industries through foundational technology breakthroughs.

GO CAPITAL finances sustainable, responsible innovation rooted in the territories, backing high-growth companies in digital, health, cleantech, industry, and the maritime/blue economy across western and national France.

Transform academic discoveries into breakthrough therapeutic companies. Partner with exceptional founders to build sustainable biotech companies with significant commercial opportunity. Leverage in-house discovery engines to de-risk company creation and accelerate time to clinic.

Backing scalable, tech-driven startups that address real social and environmental challenges, with explicit 2-3 impact KPIs set per company alongside financial metrics.

Great entrepreneurs build great businesses. We provide expansion capital, deep operating experience, and an expansive network to established, rapidly growing, founder-led companies in software, tech-enabled services, and healthcare across the Southeast and Texas, without taking control of the business.

Back passionate, emerging talent solving deep technology challenges. Support founders from napkin-stage through IPO with patient, flexible evergreen capital. Focus on biotechnology, frontier software, food innovation, longevity, and AI that maximize impact and potential.

BGF provides patient, minority growth capital to ambitious SMEs and deep tech/life sciences startups across the UK and Ireland. Founded to address the SME funding gap, BGF never takes controlling stakes, provides long-term support without fixed exit deadlines, and offers portfolio access to its talent network, operating specialists, and community platform.

Arrest the drivers of common, burdensome, population-scale health conditions (cardiovascular disease, diabetes, lung disease, chronic pain, anxiety, depression) by pairing capital with operating capability and technology to accelerate drug development, frequently co-founding and building biotech companies around specific clinical assets.

Back technical teams working on breakthrough products. We invest in seed stage companies that demonstrate technical differentiation - meaning technical or product-level superiority is a major reason for future success. We pursue investments from application layer (AI/ML) through software infrastructure to hardware layers (semiconductors, photonics).

Invest in software-driven businesses in technology and healthcare at the frontiers of AI, computational biology, physical AI, cybersecurity, and enterprise software, deliberately avoiding commoditized categories that big tech will give away for free.

We identify the teams shaping the quantum technology future and give them the funds and support they need to build world-changing businesses, backing the full quantum stack: computing, sensing, communications, and infrastructure.

Frontier technologies and medical breakthroughs offer the best opportunities to address fundamental human and environmental challenges. Diversity of founder backgrounds drives innovation and superior returns. Founders with domain expertise, technical credentials, and distinctive visions solve the world's biggest problems.

Software is eating the world, but we're eating hard tech. We are the scientific founder's partner, providing capital and co-creation to help academic researchers translate deep science into commercial hard-tech companies.

Alkemi backs bold, governance-aligned founders building scalable Indian healthcare and wellness companies with validated product-market fit, providing long-term partnership capital and hands-on operator support to accelerate market-leading companies.

Invest in deep science and disruptive technology companies that solve fundamental human problems—inequality, health, climate adaptation. We back founders with vision, instinct, and drive to scale impact.

KDT backs principled entrepreneurs building disruptive technologies across connectivity, cybersecurity, healthcare, enterprise software, semiconductors, supply chain/manufacturing, energy, and fintech. KDT differentiates through Koch Labs® — connecting portfolio companies to Koch Industries' global commercial ecosystem and subject matter experts — enabling faster commercial deployment and scaling than traditional VC.

Backs transformative deep-tech entrepreneurs pursuing technically ambitious, capital-intensive breakthroughs years before markets validate them, providing capital plus hands-on partnership to help scale.

We invest in science- and mission-driven founders building deep tech that transforms large industries for good, across Applied Science & Digital Transformation and Climate & Ocean Tech.

Eka backs founders creating positive system change across three consumer-led mega trends: Life (access and affordability in essentials), Health (reactive to preventative healthcare), and Sustainability (decarbonization in consumer industries). The firm holds that impact and financial returns reinforce rather than oppose each other.

NIF invests in cutting-edge science and engineering startups that strengthen the defence, security, and resilience of NATO Allied nations. Backed by 24 sovereign governments, NIF provides deep tech founders with unprecedented access to government procurement markets across 24 countries, connectivity to ~90 NATO-affiliated test centres, and 6,000+ Allied scientists. NIF leads initial investments with up to €15M and maintains substantial follow-on reserves.

Positron assists scientists in turning outstanding research into successful companies, providing first-check capital to scientist-entrepreneurs across the natural sciences tackling major global challenges.

Auxxo backs the strongest pre-seed and seed stage female-(co-)founded startups across Europe, driving equitable representation of women as founders and investors in venture capital.

The best biotech companies come from deeply technical founders with direct research expertise. We back early-career scientists, often PhD holders who have never written a business plan, providing capital, mentorship, and partnership to help them build world-changing technologies.

Former operators who scaled cybersecurity companies from inception to exit back founders building the next generation of cybersecurity companies, with AI as an increasing driving force across the portfolio, plus selective healthtech investments where the firm's operator value-add translates across domains.

The wise development of transformative technologies: AI that defends and enhances human flourishing, agency, and resilience, paired with frontier mental health technology including psychedelic medicine and neuromodulation.

Partner with visionary founders to turn bold ambitions into world-changing breakthroughs in life sciences, technology, healthtech, and crypto. Distinctive 'technical-risk-yes, regulatory-risk-no' filter ensures clear pathways to success.

Activating healthcare innovation through revolutionary partnerships. Optum Ventures backs extraordinary entrepreneurs transforming healthcare, leveraging deep connectivity across UnitedHealth Group, health plans, providers, employers, and patients to help portfolio companies access commercialization pathways that independent funds cannot offer.

Disruptive ideas supercharged: back seed-stage deep tech and hardware (including hardware-interfacing software) companies in the Nordics and Baltics that deliver social or environmental impact, getting involved before revenue and pushing portfolio companies to revenue within six months.

Mercia backs ambitious UK founders with early traction in software and AI, consumer, deep tech, and life sciences, and pairs capital with practical support through a long-term partnership.

Founder-aligned, patient capital for European deeptech and hardware founders across quantum, photonics, edge AI, and advanced sensing, deployed deal by deal without fixed timelines or board-seat requirements.

A domestically-incorporated Chinese private equity and venture firm investing across healthcare/biopharma, TMT, and cultural industries from seed through growth, pre-IPO, and buyout/PIPE stages.

It matters not only which companies get started, but who starts them. EF identifies exceptional individual talent before a company, co-founder, or idea exists, and builds the company from Day Zero through cohort-based co-founder matching, an equity-free grant phase, and up to $250K in formation capital (via SAFE) once a team passes its Investment Committee.

Frontier Tech fund focusing on startups that apply advanced technologies to solve Real Problems. Three core verticals: AI Software & Applications, AI Hardware & Embodied Intelligence, and AI for Science & Manufacturing. 'See them as ourselves' — we succeed when our founders succeed.

Backing innovators, outliers, creators, pioneers, and trailblazers pushing the boundaries of science and technology to solve the world's greatest challenges, with an 'all gas no brakes' commitment to founders once invested.

We empower alumni of Dutch universities to become world-changing entrepreneurs, backing founders with capital, knowledge, and a high-trust community to build the companies of the future in critical sectors, strengthening a competitive and sovereign Netherlands.

The world needs an energy expansion, not an energy transition. We back category-defining founders innovating across the natural gas value chain (Green Molecules) to meet surging energy demand from data centers, AI, and industrial manufacturing.

Revolutionize the food system and improve both planetary and human health by backing audacious entrepreneurs working at the intersection of food, agriculture, climate, and health.

Deeptech Labs is the catalyst for deep tech success: it backs seed-stage startups where a novel underlying technology is fundamental to the business, and embeds each cohort in a network of entrepreneurs, researchers, and corporate partners to prepare them for a strong Series A.

A full stack investor for a complex world, backing tech disruptors with performance, values and care. Elaia partners with ambitious, technical founders from inception to leadership across two dedicated strategies: Digital Venture (B2B SaaS, AI, fintech, adtech, e-commerce) and DeepTech Seed (energy, aerospace, robotics, biotech, semiconductors), sourcing heavily from research institutions and lab spinouts.

We invest in ambitious and determined teams that can one day become industry leaders, partnering with founders from the very beginning and supporting them throughout their growth with global operating experience.

Climate restoration through identification and scaling of 'n of 1' technology opportunities combining innovative tech, viable business models, and visionary leadership. Focus on achieving $1B+ valuations in <10 years with 'scale and speed' mentality.

Back healthcare disruptors—entrepreneurs who recognize how the industry is transforming and want to make meaningful impact. Focus on health-tech innovation excluding bio-pharma drug discovery. Leverage unique network of healthcare-industry insiders as limited partners.

Partner with exceptional founders building growing, profitable, and capital-efficient businesses in healthcare, technology, and services. Provide capital plus deep operational support via a 30+ person Executive Network and dedicated portfolio operations team.

Deep tech startups at the edge of what is possible solve critical human and planetary health problems. SOSV backs founders combining scientific rigor with entrepreneurial grit, providing not just capital but access to specialized labs, manufacturing, and global expertise networks.

Backs early-stage AgeTech, senior-care, digital-health, and technology-enabled services companies transforming the aging journey, using a senior-care operator and LP network to help with distribution, diligence, product feedback, talent, and go-to-market.

Support passionate founders forging the future. Invest in seed and early-stage companies with unique ideas that have potential to reinvent entire industries. Focus on frontier technologies that make the world better and don't prey on human frailty.

Patient Capital. True Resources. Big Impacts. S3 backs visionary founders building in Business Software and Healthcare Technology. Unique single-LP structure (a multi-billion dollar philanthropic family office) enables patient, flexible investing unconstrained by traditional VC fundraising cycles. Founded in Texas in 2005 — the largest and longest-serving VC native to Texas.

Using innovation to fix health inequities: partnering with founders building technology and service solutions that expand access to high-quality healthcare for underserved populations (Medicaid/dual-eligible seniors, rural communities, school-age youth) across primary care, mental health, kidney care, palliative care, and maternity health.

5Y Capital seeks out, supports, and inspires lonely entrepreneurs, providing support from spirit to all business operations, believing that when founders others see as crazy are trusted, the world becomes a different place.

AI-first venture capital firm investing in AI transformation and digital infrastructure across GenAI Infrastructure (AI chips, quantum, autonomous robotics), Deep Domains (fintech, healthcare, enterprise), and GenAI Agents (autonomous AI for real-world consumer and enterprise use).

AMD Ventures invests across the entire AI ecosystem — from foundational models to semiconductor hardware — advancing high-performance computing and enabling pervasive AI. Portfolio companies gain access to AMD Instinct GPU infrastructure, AMD engineering expertise (ROCm ecosystem), and AMD's enterprise go-to-market network.

Back disruptive technology innovation early and support it with a deep value-creation team through supply chain, talent, ESG, and follow-on financing help, applying Hillhouse's long-term fundamentals-driven research process to early-stage investing.

Backs early-stage companies building groundbreaking exponential technologies that can transform societies and help countries achieve higher levels of economic progress, bridging US deep-tech deal flow with a large Southeast Asian corporate and family-office LP network.

Serve industry, contribute to society, repay the nation through professional capability. Act as an industry integrator and innovation driver across advanced manufacturing, IT, new materials/new energy, life sciences, and tech-driven consumption, pairing capital with operational and industrial-resource support.

Backing new ideas, clear vision, and an obsessive pursuit of change. Triple Point Ventures partners with exceptional early-stage founders across fintech, health, climate, and data & AI, aiming to meet founders early, move quickly, and lead pre-seed and seed rounds.

Invest in early-stage technology and tech-enabled services that solve health systems' most pressing challenges, leveraging an LP base of national health systems for distribution and validation.

Extraordinary companies are built by driven founders whose mission to improve the health of people and planet is inseparable from their product. We partner with technical founders building technology solutions to the world's most important challenges across climate, health, biotech, and enabling technologies.

We believe in the disruptive nature of science- and technology-driven innovation. We focus on cross-industry and interdisciplinary projects to discover innovations at the nexus of technology domains where capital-efficient solutions can unlock significant value.

Support the realization of start-ups' dreams by sharing the aspirations of entrepreneurs, establishing trust as a capital partner, and assisting throughout all growth stages — from seed to IPO. MUCAP invests across all industry types and stages with particular depth in life sciences (dedicated department) and new industrial fields requiring patient capital.

Backing immigrant entrepreneurs building companies in Europe. Immigrants account for ~50% of US and ~40% of UK unicorns. NLV spots and supports this talent before the market catches up, investing unconditionally as the first check before lead VCs are in place.

Permanent balance-sheet investor backing highly defensible, category-defining, mission-driven companies solving the world's biggest problems. Focus on founders transforming legacy industries with emphasis on diversity, equity, and inclusion.

The most enduring companies are created by founders willing to commercialize real science and scale real systems. We focus on hard tech at the intersection of computation and physical sciences—aerospace, biotech, energy, materials—where technical execution is the moat.

Unearth, invest and grow startups into global leaders. iGlobe targets game-changing innovations at the frontier of deep tech — semiconductors, AI, quantum computing, and biotech — with a global orientation and a Singapore hub. Founded by Soo Boon Koh, Singapore's first female VC, the firm brings 25+ years of cross-border investing expertise and a top-quartile performance record.

A growth accelerator for ambitious French companies built on a frank, direct and rapid entrepreneur-investor relationship, backing founders through start-up to pre-IPO growth phases with resilience and collective intelligence.

Europe's next generation of climate, resilience and deep-tech companies is being starved at the earliest, riskiest stage; a heavyweight operator network combined with a pre-seed fund closes that gap.

J2 Ventures invests in early-stage companies developing technologies that advance both U.S. national security and commercial markets. The firm backs founders whose innovations strengthen national security while improving safety, health, and connectivity for everyday life. J2-backed companies receive capital plus deep expertise across government, defense, science, healthcare, and finance — and on average raise $2 in non-dilutive funding for every $1 J2 invests.

UVC Partners invests in European B2B tech startups across DeepTech, ClimateTech, Mobility, and Software/AI, from pre-seed up to Series A, leveraging the UnternehmerTUM ecosystem to help portfolio companies build sustainable category leadership.

Investing where biology and technology converge, backing category-defying founders whose work blurs the line between life sciences and technology.

We find, fund, and empower entrepreneurs who turn technological advancements into hardware and software products that fundamentally improve industrial value chains, aiming to build category winners that form the backbone of a thriving, sovereign European industrial ecosystem.

Support innovative healthcare software and services companies that make the U.S. healthcare system more affordable, sustainable, and consumer-friendly, backed by an LP base of major health plans, health systems, and health technology companies.

Partnering with founders building world-changing innovation by blending the global power of Hitachi with the speed of independent venture investing, across Digital, Industrial, Environment, and Healthcare themes.

We draw startups that transform society with imagination and technology into a spiral of growth, focusing on vast market opportunities (industry transformation, DeepTech, industry-agnostic advanced technology) paired with strong management teams.

Boom Capital invests early in founders building at the frontiers of science. We position founders as scientist-protagonists and back highly technical teams tackling ambitious, non-obvious problems in genomics, machine intelligence, aerospace, new chemistries, and related deep science sectors.

The combination of purpose and profit amplifies performance. The next generation of extraordinary companies will harness technology to solve system-critical problems that fundamentally improve the lives of people and the longevity of the planet, across Health and Wellbeing, Economic Empowerment, and Sustainable Planet.

Progress in food, agriculture, and human health lags other sectors due to structural constraints. We invest in deep technologies that remove these bottlenecks at scale—whether AI, biology, robotics, or materials science. We're not intimidated by threats to the status quo.

LGV backs early-stage and growth-stage innovators with the strategic strength of LG Group's global resources. The fund invests in companies that stand to gain exceptional value from partnerships with LG's manufacturing, display, chemical, and energy business units, with a strong focus on AI, biotech, cleantech, and advanced materials.

Government policy and regulation are usually treated as a hazard to hedge against, but certain policy decisions accelerate new market opportunities or create entirely new markets. We identify early-stage, globally-sourced healthcare technology companies positioned to benefit from U.S. regulatory tailwinds.

Making the physical world machine-readable. Humans bridge disconnected engineering systems, factories, supply chains, and infrastructure through experience and intuition; intelligent machines cannot. Omni invests in the technologies building the connected data foundation AI requires to operate in the physical world.

First-cheque, pre-seed-focused investor backing exceptional, sector-agnostic founders solving big problems, offering trust, speed, and candid support rather than cheerleading.

Galvanize invests at the intersection of energy innovation, resilience, and intelligence, backing the 'New Economy' companies essential to electrification, rising power demand, industrial modernization, and digitization -- from pre-seed food/agriculture/ocean/forestry ventures (Ponderosa) through growth-stage energy transition and AI-infrastructure companies (Venture & Growth).

EPIC Ventures backs early-stage technology companies building in the information economy, with a focus on enterprise SaaS, healthcare technology, cybersecurity, and future of work. The firm believes the best way to build lasting companies is through genuine partnership with founders — providing capital, strategic guidance, operational expertise, and deep network access. Founded in 1994, EPIC helped build the Utah tech ecosystem and continues to be the foundational VC of the Mountain West.

We back deeply technical founders solving hard problems with innovative technologies. Combining capital with go-to-market expertise and structured fellowships, we partner with founders who have authentic personal connections to their problems and bring novel technological approaches to market.

Back outlier founders with unconventional ambition and deep-rooted urgency operating outside conventional wisdom. We believe the best companies are built by rare entrepreneurs who can filter out 95% of typical VC advice and construct exceptional talent and culture.

Sandwater backs early-stage deep-tech and impact companies that can improve climate systems, energy infrastructure, healthcare delivery, and industrial productivity. The firm favors software-hardware hybrid businesses with technical differentiation, measurable real-world impact, and a path to scale across the Nordics and Northern Europe.

We invest in deep tech for food - solving the hard underlying problems in food and farming with new technology built on scientific discovery and solid engineering.

Backs trailblazers solving hard problems in large markets through deep technology investments across Intelligence (AI, computing, quantum), Human (health, medicine, wellness), and Planet (sustainability, energy, space).

Back mission-driven founders addressing significant global challenges through leading-edge technology. Provide flexible and patient capital, leveraging our time, resources, and networks to support portfolio company success. Focus on founders with authentic social and environmental missions alongside commercial viability.

Empower ambitious founders with capital, expertise, and network to build and scale transformative ventures, prioritizing startups that advance Saudi Vision 2030 and can localize frontier technology in the Kingdom.

Global industry is undergoing its most profound technology transformation in over a century. Calibrate backs visionary founders scaling proven deep tech — AI, computer vision, robotics, automation — to transform major sectors including manufacturing, logistics, healthcare, agriculture, and enterprise services. They invest in companies generating early recurring revenues and ready to scale, seeking market-ready deep tech with large-scale applicability.

Elkstone backs exceptional Irish (and increasingly all-island) entrepreneurs with the vision, passion and grit to build category-defining global companies, layering private-client and institutional capital into EIIS-qualifying early-stage venture funds.

We back the boldest, most ambitious founders that seem unlikely to succeed, investing our own capital with no fund clock so we can remain invested indefinitely.

Invest in founders building radically different technology companies with unique business models or distribution strategies. Focus on high-velocity founders who are maniacs on a mission.

Great products change the world. We fund the people who build them. The Product Alpha Effect™ uses signals from 600,000 product leaders to identify outlier companies at the Discovery Stage before the market recognizes them.

An opportunistic, generalist fund that co-invests alongside top-tier VCs in startups featured on The Pitch podcast. Built-in dealflow from 30M+ downloads and 600K+ newsletter subscribers; the fund's edge is access to a constant, pre-vetted pipeline of founders who apply to pitch on the show.

We invest before investing: writing the first institutional check into founder-led teams building technology-driven, sustainable businesses that address real, structural problems across DeepTech, GreenTech, Digital Health, and FinTech.

Backing frontier, technically ambitious founders solving civilization-scale problems in energy, biology, maritime logistics, defense, and human performance rather than incremental software.

As the world becomes more information-rich, most transformative new companies will leverage data science, machine learning, and advanced computing power. We back founders building breakthrough solutions at this intersection.

TEN13 is a network-driven VC that curates vetted early-stage deals for a 500+ member syndicate of operators, investors, and founders, sourcing and diligencing rounds while letting members select which deals to join.

GV backs innovative founders moving the world forward, operating on long time horizons and dealing in decades, not rounds. Since 2023, GV has accelerated its focus on AI-native companies across infrastructure, applications, healthcare, and developer tools — with approximately 80% of new European investments now in AI.

Backing IP-led innovation in science, engineering, and technology that can create durable, defensible value. Evaluates team drive, TAM scalability, and technology defensibility. Provides patient financing suited to hardware-adjacent, R&D-heavy businesses.

Frontier technology companies transforming legacy industries in the US Midcontinent. We back experienced technical founders from energy, healthcare, manufacturing, and logistics sectors who leverage deep domain expertise to build high-growth B2B tech companies. Capital efficiency and exponential productivity improvement are key filters.

Human-driven, community-powered, tech-augmented investing that backs real scientific, societal, and environmental shifts rather than trend-chasing or algorithmic sourcing.

IMM backs innovative entrepreneurs across multiple stages with a single platform spanning venture capital, growth equity, infrastructure, and secondary capital. The firm emphasizes partnership, long-term value creation, and operational support, especially where capital, scale, and governance complexity all matter.

Gender-balanced founding teams outperform. We back companies founded or co-founded by women (30%+ women equity ownership at pre-seed) across Healthtech, Fintech, Sustainability, and Deep Tech, leading from pre-seed to Series A across France, Europe, and the US.

Building a healthier, more efficient, and more resilient food system by backing entrepreneurs who apply science and technology to the agrifood industry's most pressing challenges, bridging Italy's established food industry with breakthrough AgriFoodTech innovation.

We back outliers of the outliers - founders with unreasonable ambition who can filter out 95% of conventional VC advice. We seek category-defining companies aiming for $10B+ outcomes, not incremental improvements. Our conviction is deep, selective, and global. We don't meddle - we provide brutal honesty, talent upgrades, and capital for survival through near-death moments.

We invest in technical breakthroughs that overcome the world's greatest challenges. We partner at inception with technically brilliant dreamers who see past impossible to inevitable. We evaluate scientific opportunities through both commercial potential and human impact lenses.

We invest in founders with laser-focused ambition to define technology across AI and deep tech. No stage is too early. Our role is to be their first call, fiercest champion and long-term partner from idea to impact.

We back entrepreneurs using computational approaches (AI, simulation) to solve trillion-dollar problems in climate, health, industrial transformation, and national security. Deep tech requires patient capital and scientific rigor.

Dedicated to advancing Canadian agriculture, Verdex invests in the entrepreneurs, technologies, and businesses shaping the future of food and agriculture, providing patient capital suited to agriculture's seasonal cycles and long validation timelines.

Entrepreneurs will change the trajectory of climate change. We build ventures from pre-team/pre-idea founders with the potential to mitigate at least 10 million tonnes of CO2e annually at scale.

We invest in underrepresented outperformers: first- and second-generation migrant founders, women in male-dominated industries, and founders from socioeconomically disadvantaged backgrounds, who we believe disproportionately possess the resilience, work ethic, and ability to inspire that predict founder success.

iAngels is a gateway for global accredited investors to access Israel's tech ecosystem, applying a data-driven, proprietary diligence process (including a founder leadership/psychological assessment) across sectors, with an Investment Committee requiring unanimous GP approval.

Founders with military backgrounds and demonstrated grit combined with differentiated dual-use technology create exceptional venture opportunities. We focus on pre-seed and seed-stage companies solving meaningful problems that make the country and allies safer while having strong commercial applications.

We back the technological platforms of tomorrow — the picks and shovels of Europe's reindustrialisation. High-conviction early-stage investor in frontier and dual-use technology from space and healthcare to industrial resilience, rooted in the Baltic Sea Region, backing founders from pre-seed to exit and beyond.

Where breakthrough science turns into world-changing companies. We back scientists and engineers at the earliest stages—pre-formation and pre-product—at the intersection of AI, engineered biology, next-gen compute, and hard science. If it's too early for everyone else, it's probably right for us.

NEA partners with ambitious founders at every stage of company building, from pre-seed through IPO. They invest at the intersection of technology and healthcare, believing the most transformational innovation occurs where deep domain expertise meets world-class technical founders. NEA serves as both capital provider and active operator.

Evaluate risk objectively, confront fear rather than avoid it, and prepare in advance for shifts in the capital markets; back technology-oriented startups with defensible barriers, global scalability, independence from conglomerate patronage, and exponential growth potential.

Exceptional founders backed at pre-seed and seed with both capital and hands-on operational support—talent, GTM, fundraising—build the most enduring companies. Pear is founder-first: founders-and-operators turned investors who have been in founders' shoes.

Back the global winners of tomorrow through disciplined venture capital and growth equity investing. We are a trustworthy partner providing capital, operational expertise, and access to pan-Asian networks. Fund-oriented professional VC with fundamental philosophy of quality, responsibility, and stability.

Back ambitious technology and healthcare founders in Asia, Europe, and Israel, providing not just capital but access to a global ecosystem spanning 350+ portfolio companies across four continents. Fidelity backing allows more flexible and focused support than typical VC.

Backing transformative founders building exceptional companies across all sectors

Back ambitious founders from Central and Eastern Europe and the diaspora building large-market, 10x-better products, favoring high-risk/high-upside bets over safer, modest-return opportunities, grounded in market data rather than intuition.

Boreal invests in capital-efficient Canadian B2B technology companies with early product-market fit, partnering with founders to build scalable go-to-market engines. The firm focuses on sectors systematically overlooked by larger funds: vertical SaaS & AI, industrial tech, fintech, digital health, and manufacturing. With Fund II, Boreal will not cover medtech and will not take scientific or pure R&D risks. Provides more formalized GTM support via JD Saint-Martin's operational expertise. Targets 15 investments from Fund II, 90% at seed stage with $1.5M-$3M initial cheques.

Backing Europe's most ambitious founders from Series A and beyond across SaaS/enterprise software, deeptech, healthtech, and consumer software, using a permanent-capital listed structure to stay invested through growth and pre-IPO stages.

Channel capital from a large base of retail and institutional investors into vetted, growth-stage Spanish companies with strong public narratives, giving individual investors direct equity access normally reserved for institutional VC.

Invest in and provide business-development support to startups building next-generation technology, bridging Japanese and global markets by combining Digital Garage's startup network with Daiwa Securities Group's capital and financial infrastructure.

Backs 'The Audacious Entrepreneur' as a generalist, multi-stage Indian VC, sourcing untapped white-space opportunities across SaaS, consumer, fintech, healthtech, agritech, climatetech and deeptech, with a fast-turnaround Sonic seed program and growing focus on AI, spacetech, defencetech and quantum.

Backing the best founders, not just the best-connected. We assess founders on their qualities, not CV or past experience. We focus on founders building solutions for climate equity, economic empowerment, and healthy ageing.

We invest in early-stage information technology and biotechnology companies in Colorado and the Mid-Atlantic. Our philosophy is rooted in mountain guide principles: careful pattern recognition under uncertainty, patience in waiting for proper conditions, and a commitment to realized returns over paper valuations. We provide hands-on operational partnership, board-level involvement, and access to deep regional networks built over decades.

We back bold, early-stage founders building disruptive innovations deeply rooted in science, engineering, and technology, across Novel Energy & Planetary Health, Human Longevity & Synthetic Biology, Beyond Earth & Space Tech, Advanced Manufacturing, and AI Led Software. We prioritize exponential over incremental change and are often the first institutional check.

Make no little plans. Support revolutionary (not evolutionary) ideas that transform industries and benefit society. We partner with entrepreneurs solving massively multi-disciplinary problems at the intersection of AI, data, biotech, and deep tech. Our style of in-the-trenches venture capital doesn't scale—we make fewer than 10 investments per year so we have time to roll up our sleeves with every team we back.

The next generation-defining companies will be built by founders who thoughtfully harness AI development to solve real-world problems at scale. Investment focus spans infrastructure to healthcare, enterprise software to financial markets, wherever AI can drive meaningful transformation.

Exceptional founders with strong conviction deserve capital, mentorship, and partnership from day one. We back category-defining companies at the earliest stages.

Partnering with entrepreneurs to transform their ideas into world-changing companies, concentrating on cybersecurity, enterprise/cloud software, consumer (incl. e-commerce), and healthcare (medtech, biotech, IT-enabled services), typically leading Series A/B rounds and taking board seats.

We invest in businesses in established markets with solid fundamentals, genuine customer demand, and a clear exit path, across Tech-Enabled Services, Vertical Software, and Mittelstand Transformation, with a focus on the DACH region.

IBB Ventures backs Berlin-based founders building consumer, healthcare, industrial, and software companies that can scale from the city into broader markets. The firm favors practical innovation with a clear path to market launch and durable long-term value creation.

We invest exclusively in AI-first companies where advances in artificial intelligence are the primary driver of product capability, competitive advantage, and long-term value creation. We are deeply coupled to the frontier of AI research and industry, enabling us to identify emerging technical inflection points and structural shifts early.

We invest in people who will transform the physical world. Near frontier technology solving climate change, disease, armed conflict, poverty, and existential risks. Technical founders building capital-intensive, long-horizon companies.

Malpani Ventures funds frugal innovation in India, backing founders who run their company as a business rather than a startup, with patient capital prioritizing cash flow, customers, and capital efficiency over blitz-scaling.

We back founders on a mission to industrialize scientific and technological progress. Hardtech startups solve difficult technological problems using interdisciplinary mixes of technology and engineering. We provide patient, supportive capital and community to help founders navigate R&D cycles and build technically defensible products.

We invest €100k to €15M in entrepreneurs with the capacity to create differentiated technology-based products and services, backing the crazy, contrarians, and outliers from pre-seed to Series B across Southern Europe and Latin America.

Investible backs the visionaries advancing humanity through technology, investing at Pre-Seed through Series A alongside Club Investible, its global syndicate of 250+ investors, and activating its network to help founders scale.

Backing seed-stage, tech- and data-driven B2B software companies across Europe with global ambition. Focus on Agility Drivers (verticalized, consumerized, XaaS solutions) and Seductive Solutions with genuine product-market fit. Invest in AI-first and AI-enabled businesses as well as frontier tech (BioIT, Space, DLT, Quantum Computing).

Kakao Ventures finds the 'one reason' a startup will succeed — the single differentiating capability that makes a mission inevitable — and provides capital and co-pilot support to help that potential bloom. They focus on mission-driven founders in deep tech, ICT services, digital healthcare, and gaming at seed and pre-Series A stages.

Founder-centric, largely sector-agnostic investing across Europe, backing technically strong founders building globally ambitious companies, including capital-intensive deep tech and moonshot bets alongside traditional software and consumer businesses.

We back ambitious UK founders building technology, MedTech, and SaaS businesses with commercial or clinical validation, providing capital, network access (IW Connect), and dedicated growth support (IW Catalyst).

The Maghreb produces world-class scientific and engineering talent that lacks a bridge to global capital, strategic customers, and later-stage co-investors. MEDIN backs the person and the science before a market fully exists, then bridges founders to Europe and Silicon Valley.

Founders from Australia/NZ, Israel, and Southeast Asia will shape the future of global technology. We prioritize people above all else, backing entrepreneurs with compelling visions who assemble talented, mission-driven teams to tackle large, important problems, and back them repeatedly over time.

We invest in technology-driven transformational companies shaping the future of business, entertainment and society. We foster Sony's future businesses through strategic early-stage venture investments, seeking technologies with potential to transform industries while building synergies with Sony Group business units.

We democratize venture capital by providing individual accredited investors with professional-grade access to elite venture opportunities. We leverage our massive 850,000+ community network and 11,000+ investors to create unique value for founders, sourcing and diligencing deals alongside top-tier VCs (a16z, Sequoia, Khosla) without leading rounds. Our network is our competitive advantage—it compounds value for all stakeholders.

Europe's first cheque fund: the first institutional investor for exceptional European (and European-origin) founders, helping them go from 0 to 1 and reach product-market fit, backed by anchor corporate relationships with Axel Springer and Porsche.

Invest in only two kinds of technologies: those that move humanity toward utopia, and those that hold the line against oblivion. Back n-of-1 visions for an era of Black Swans—unconventional companies solving civilization-scale problems that others dismiss as too early, too risky, or too misunderstood.

Back founders building iconic companies that transcend boundaries. We invest directly in their growth to make them unbreakable. Founded on principle that luck isn't made, it's engineered. Founders are our customer, not LPs. We always vote shares with founders and provide 1% non-dilutive founder development capital alongside every first check.

Olive Tree Capital invests in groundbreaking technology and life sciences companies guided by the Golden Rule philosophy. As an evergreen vehicle without asset class limitations or holding period constraints, OTC can be a long-term partner to founders across any stage and geography.

We back founders with compounding talent, a fast clock speed, and the conviction to make bold, insight-driven bets, and support them with a Collective of senior operators who open doors, make introductions, and help close key hires and customers.

Breakthroughs at the convergence of technology, science, and humanity improve how we live, work, and experience the world. We invest in transformative technologies for human performance and wellbeing.

Investing in mission-driven founders who identify real customer needs with innovative, sustainable business models, across Consumption, Wellbeing, and Productivity — backed by patient, family-office capital and a Mittelstand/industrial network.

Artificial Intelligence will disrupt every industry. Flying Fish invests in companies where AI/ML serves as foundational technology across three pillars: Applied Intelligence (AI transforming enterprise workflows), Foundational AI & Infrastructure (core ML tooling and training), and Hard Sciences (AI accelerating biology, materials science, and drug discovery).

Back early-stage entrepreneurs shaping the industries that run the world, with deep domain expertise across AI & Automation, Health & Bio, and Logistics & Maritime, and true operating partnership beyond capital.

Spark Capital backs transformative products built by creators with genuine vision and technical depth. We believe that the best way to evaluate a founding team is not through credentials or market analysis, but by experiencing their product firsthand. Product comes first, and everything else follows.

Find and accelerate early-stage Latin American startups with defensible technology through a large-scale scouting program (Discovery-A), pairing capital with hands-on mentoring and a bridge to US Series A financing.

Turn sci-fi into sci-fact by backing founders solving the most vexing puzzles facing humanity. We believe in counter-conventional solutions and contrarian positions in deep technology. We champion companies working at the intersection of breakthrough science and transformational technology, led by visionary founders who are equal parts mad scientist and business mastermind.

Help founders succeed by combining capital ($120K-$250K), intensive mentorship (3-month program), and access to a powerful global network of 1,500+ mentors. We invest in founders at the earliest stage with conviction and vision, regardless of sector or geography. Our #GiveFirst philosophy drives us to help without expecting immediate return.

Great venture returns come from revolutionizing existing, mission-critical industries burdened by legacy infrastructure, not from chasing trendy new sectors. We back seasoned operators solving messy, complex problems in healthcare, agriculture, construction, and industrials with technology that becomes truly mission-critical.

Invest pre-seed and seed in technical teams tackling root-cause cost challenges in healthcare and Main Street productivity — the two sectors most critical to American economic resilience and most underserved by traditional VC. Enter post first customer, pre-PMF, and provide hands-on operator support to accelerate distribution and prepare for Series A.

BGV backs hands-on, cross-border enterprise AI startups operating under the Enterprise 5.0 framework — companies that combine intelligent machines with human ingenuity to drive leapfrog productivity improvements. They focus on vertical AI (industry-specific, proprietary data) and horizontal agentic platforms (cross-functional automation), with a strong preference for immigrant founders pursuing US go-to-market strategies from France, Israel, and India.

Great physical products, protected by strong IP and built by design-literate founders, can generate outsized returns while solving real consumer, health, and environmental problems. Every deal is structured to be SEIS/EIS eligible.

FSE Group provides market-gap funding to high-growth UK SMEs, pairing debt and equity capital with long-term regional support, job creation, and measurable economic impact.

Intelligence is coming into the physical world through AI and robotics applied to atoms rather than bits. We back capex-heavy, long-horizon bets in hard-to-abate decarbonization sectors and hardware-heavy industrial systems that many traditional early-stage funds avoid.

Rule30 uses a fully algorithmic decision engine to identify outlier founders at pre-seed and seed stages across Europe and North America. The fund removes human bias by analyzing founder experience, educational background, network evolution, and career trajectory — excluding names and photos. The algorithm ranks founders into top 10%, 3%, and 0.1% tiers. An index-style strategy of 75-85 bets targets ≥3x minimum returns with 97.5% confidence.

Early-stage companies leveraging frontier technologies (AI, gene editing, synthetic biology, advanced diagnostics) to transform human health, cure disease, and strengthen global resilience. Data-driven, engineering-first approaches combined with cellular biology create transformative healthcare companies. Focus on companies that solve problems affecting everyday people globally with platform potential across multiple indications and therapeutic pathways.

It's time for 'Asia to Global' — Asia2G backs Korean and Asian technical founders in deep-tech, enterprise, and infrastructure categories, and helps them expand into the US through GTM strategy, fundraising support, executive recruitment, and product-market fit expertise.

Sand Hill Angels backs seed-stage, high-tech companies with large and growing markets, well-defined problems, disruptive solutions, defensible technology, and strong teams with demonstrated ability to execute. The group leverages 145+ experienced angels to provide capital, mentorship, and network access across the Silicon Valley ecosystem.

All you need is a Unique Insight. Frst backs exceptional, ambitious founders on Day One, often before there is a product, team, or incorporated company, evaluating opportunities through Ambition, Vision, and Execution.

Bespoke Capital for Enduring Impact. Gobi invests where capital alone is insufficient — requiring deep local relationships, sustained engagement, and informed judgment across Asia's diverse and complex markets. They focus on technology companies solving structural inefficiencies across underserved Asian markets, from fintech to deep tech to sustainable infrastructure.

We invest when we identify real technological differentiation - proprietary models, novel applications of existing AI, or unique data advantages that create sustainable competitive moats - backing founders who can turn breakthrough AI innovation into market-defining, enterprise-adopted companies.

We back mission-driven founders building breakthrough technologies to solve humanitys most complex, large-scale challenges. Like an iceberg, the most valuable invention is frequently invisible; we look past surface-level applications for deep, foundational innovation.

M25 backs technical and operating founders building tech companies headquartered in the Greater Midwest, applying a rigorous scorecard (team, market, product, traction, exit & growth, funding, business plan) to reduce risk at the earliest stages while relying on an extensive regional network to syndicate rounds.

Expand the AI ecosystem by backing technology visionaries solving complex problems to reshape our world. Focus on game changers and market makers in AI, robotics, biotech, autonomous vehicles, and applied AI. Leverage NVIDIA's unique position as GPU infrastructure leader to identify and support companies that will drive adoption of NVIDIA technology.

Healthcare innovation is a team sport. We identify promising healthcare technologies early in their life cycle and invest much more than capital to help our teams become world-class enterprises. We provide clinical expertise, operational guidance, and network access from a team of practicing physicians and healthcare operators.

Back dual-use technologies serving both commercial and government markets. Founded as investment community response to 9/11, we bring unmatched expertise from NSA, CIA, DARPA. We seek founders building innovative cyber, AI safety, and advanced technologies with meaningful impact on national security and commercial markets.

The agrifood value chain has reached a tipping point where incremental change is not enough; systemic disruption and regeneration of the food and agriculture system is required to restore human, planetary, and economic health.

Sixth Street Growth provides flexible, patient capital to mid- and late-stage technology companies, pairing growth equity and bespoke credit solutions with deep operating expertise through its 'More Than Capital' platform. Focus areas include enterprise SaaS, fintech/payments, healthcare IT, cybersecurity, and data infrastructure.

Back deep tech companies enabling AI at the infrastructure layer (chips, hardware, algorithms) and AI-powered applications previously impossible without AI — with a current focus on GenAI, embodied intelligence, autonomous driving, and healthcare AI. Leverage Baidu's unique resources: engineering talent, data annotation infrastructure, and ecosystem customer relationships.

Patient and intelligent capital for rapidly scaling entrepreneurial companies with a transatlantic footprint. US funds target Midwest Series A+ companies with ARR >$3M; UK funds target Series A/B companies with £1M+ revenue. Hands-on operational support through the Beringea Scale-Up Academy and transatlantic network.

Expertise unlocks AI's full potential. We back technical founders who harness deep domain knowledge, apply novel AI applications, and push boundaries to create transformative breakthroughs in healthcare, life sciences, and enterprise.

We invest in early-stage AI-driven startups founded by top technical talent from MIT, Harvard, and Boston ecosystem. We believe transformative AI innovation is emerging from university-affiliated founders backed by comprehensive operational support, mentorship, and access to world-class networks.

Building next-generation food and agriculture technology companies that commercialize solutions for sustainable production, equitable distribution, and healthy consumption. Partners with strategic investors to drive systemic impact in food systems.

The next era of value is built on atoms, not apps. We back founders who start in the laboratory — those with genuine scientific breakthroughs, from semiconductors to biotech, robotics to drug discovery. We provide patient capital for the long development cycles that breakthrough science demands.

Broad-spectrum deep-tech and technology investor with particular conviction in AI, climate tech, and healthcare, pairing capital with hands-on operational support and open-innovation partnerships between startups and major Japanese corporations.

Contrarian venture firm investing in scientific and technical breakthroughs. We identify white-space opportunities where technical founders are solving previously unsolvable problems. We combine capital with deep domain expertise, research capabilities, and operational support to help founders scale from idea to commercialization.

The primary constraint for seed-stage, science-based entrepreneurs is access to experienced business judgment. CDL provides objective-based mentoring from accomplished entrepreneurs, angels, and scientists to help founders prioritize tasks and de-risk their businesses.

Operationally-focused food and beverage growth equity, pairing capital with an in-house operating team (channel strategy, ERP, COGS, co-manufacturing, commercialization, regulatory) to accelerate visionary CPG, food, and beverage companies, plus a smaller food tech sleeve in fermentation and cellular agriculture.

We partner selectively, care deeply, and strive for excellence across sectors, helping founders leverage our decades of experience, extensive network, and valuable insights to build scalable and sustainable businesses in India.

Resilient, Efficient, Clean, Affordable, Secure: emerging technologies can transform how the world produces, powers, and consumes without sacrificing current standards of living, especially technologies nearing price parity with incumbents and strengthening secure, resilient supply chains.

We back the foundational layers of progress. Developer platforms that accelerate creation. Robot operating systems that make autonomy real. Simulation engines training the next generation of AI. Formal verification securing billions in value. Foundational systems that quietly compound—built by founders who see elegance in complexity and possibility in constraints.

Sierra believes enterprise software is being fundamentally transformed by cloud computing and AI. They invest in technical founders building the next generation of enterprise solutions that deliver superior ROI through better efficiency, automation, and capability. The firm particularly focuses on infrastructure, security, healthcare innovation, and emerging deep tech.

Mission-driven founders building transformative companies. FPV backs missionaries, not mercenaries—founders with genuine conviction in solving hard problems and willingness to pursue 100-year visions. Focus on founders who are misunderstood initially but recognized as geniuses for changing the world. Founder service is their North Star—they aim to be the founder's first phone call with operational support from experienced partners.

Technology-based economic disruption of large markets through black swan investments. We seek founders with domain expertise and unreasonable conviction to build billion-dollar companies solving the world's largest problems.

The AI-first transformation of business will be as big as digital, mobile, and cloud combined. We invest in companies building the AI-first technology stack: data foundations, AI tools, autonomous applications, and product-led growth companies that accelerate adoption. Founders building at any layer of this stack can reach goals and uncover opportunities previously unattainable.

Strategic self reliance (Atmanirbhar Bharat) in deep technology and sectors of critical importance -- National Security, Defence & Aerospace, Digital Communications -- is both an existential need for India and a large commercial opportunity.

We invest in people solving difficult problems and building category-defining products in healthcare. We partner with visionary leaders at the intersection of medical technology and digital health to create transformative solutions that improve patient outcomes.

Redstone is a European specialist VC platform that backs early-stage companies across DeepTech, Industrial, Energy & Infrastructure, FinTech, Health, Social Impact, Blue Economy, and Venture Debt. It combines thematic conviction, data-driven sourcing, and a hands-on operating style.

The space economy represents the next frontier for transformative economic opportunity and meaningful impact. We back pioneering founders building the technologies and services that enable humanity's expansion into space while creating value on Earth. We apply financial discipline (Wall Street cash-flow and intrinsic-value approach) to identify sustainable, scalable space businesses.

Systematically back clinically rigorous, behaviorally grounded wellbeing startups tackling stigmatized areas—alcohol use disorder, menopause, mental health—using stigma as an investing edge and insisting on consumer-grade UX. Solve the Wellness Gap: the quantifiable delta that has grown as GDP per capita increased while physical and mental health stagnated.

Top-performing SaaS venture fund that identifies exceptional founding talent at the earliest stages and takes an active role in their growth — particularly in scaling go-to-market and sales teams. Prioritizes founding team potential over traction or revenue metrics.

Back founders building durable, foundational companies in large, important markets where a durable company needs to be built and no one has built it yet, avoiding incremental technology plays.

AI technologies are increasingly running the enterprise, making trust critical to scale. We invest in the companies that create that trust and the founders who scale them, with a leading focus on Infrastructure Intelligence — software that gives asset-heavy industries (energy, real estate, logistics, agriculture) the ability to sense, model, and act on their environment in real time.

Life sciences is experiencing unprecedented innovation through TechBio—companies that merge technology and biology. We partner with passionate, accomplished founders with unique insights to solve daring life science problems and significantly impact patient care. We provide capital, operational support, scientific guidance, and industry relationships to build transformative companies.

Partner with visionary European founders at seed and Series A, leveraging the team's own operator experience and a network of 150+ international co-investors. Sector agnostic (excluding life sciences and crypto) with ~50 companies per fund. Strong focus on capital efficiency, unit economics, and realistic paths to profitability. Co-investor by default; will lead when it adds value.

The best companies will be built by technical founders - engineers, researchers, and scientists who have experienced a problem viscerally and are compelled to solve it. We invest in tools, platforms, and infrastructure for technical builders, and we partner with founders to help them evolve into leaders of generational companies.

b2venture backs outlier entrepreneurs at the earliest stages across Europe, leveraging a multi-generational community of founder-turned-angel-investors to provide capital, expertise, and network access from seed through IPO.

We back exceptional technology founders from Southeastern Europe and its diaspora — builders with deep technical DNA, domain obsession, and the ambition to win global markets, focused on Future of Work, Fintech, and Health.

Healthcare is a multi-agent system whose historical limits on information and coordination can now be removed by AI; Redesign co-founds and builds next-generation healthcare companies from scratch, backing exceptional founders at the earliest stage and applying an internal AI knowledge graph (Atlas) plus marquee institutional partnerships through exit.

We partner with entrepreneurs who transcend the constraints of space and time, seeing beyond the obvious to chart new frontiers, enable new capabilities, and create new markets.

The Tulane University alumni network is an underleveraged pipeline of entrepreneurial and technical talent; channeling capital into Tulane-connected founders builds venture returns while rebuilding Louisiana's startup ecosystem.

The founder is the wedge—category comes after. We invest at the event horizon, in what's very early and unexpected. Uncommon people, ideas, and technologies where new markets and movements are on the brink of inevitable. We move fast, write lead checks, and stay out of founders' way.

We back deep-tech and IP-led startups when the world still calls them too early, at the edge where science becomes engineering. We chase inevitability, not hype.

Back industry innovators and ecosystem creators building transformative TMT businesses with global potential, leveraging Jason Zeng's Tencent network and Asia-Silicon Valley cross-border expertise. Focus on founders with proven execution capability and long-term vision.

Connect innovative startups to 550+ corporate partners who have real business problems to solve. Our platform creates a flywheel of pilots, enterprise customers, and follow-on capital for founders who value long-term partnership and have credible paths to $100M+ ARR.

We invest in startups building the technologies, infrastructure, and services that will be integral as we progress towards a Type I Civilization on the Kardashev Scale. Humanity is at ~Type 0.73 civilization and estimated to reach Type I in ~100 years. We fund moonshot technologies solving fundamental problems in space, robotics, AI, and human longevity.

Long-term, concentrated investment in high-quality innovative growth businesses across public equity, venture capital, and growth equity. Applies six investment criteria universally: sustainable above-average earnings growth, leadership in a promising business space, significant competitive advantages, clear mission, financial strength, and rational valuation. Integrates public and private market insights for superior sourcing and diligence.

We invest in hard tech and hard sectors—companies building solutions to difficult, underexplored problems that others won't. Unlocking society's potential depends on founders willing to build what others won't. We're hyper curious, drawn to difficult and underexplored areas.

Founders are the key to realizing a startup's potential; capital is the key to realizing a scaleup's potential. We back disruptors delivering a 10x value proposition to large markets, from pre-seed through growth.

Passion Capital backs outstanding European founders building in AI, FinTech, and Enterprise Risk, investing at the pre-seed and seed stage—often before revenue or product exist. Europe's first operator-led VC fund, pioneering Plain English term sheets. Writes initial cheques of £400K–£500K as the founders' first institutional investor.

Actively champion founders and entrepreneurs, fostering a culture where startups thrive, while serving as the bridge to Sony that drives deeper engagements through technical expertise and network access. Focused on DeepTech, Entertainment, EnterpriseTech, Fintech/DLT, ClimateTech, and Location-Based Entertainment.

Invest in companies addressing fundamental societal needs. Provide Talent/Capital/Attention platform via in-house content and advisory network. Mission-driven investments with specialized expertise in healthcare, climate, robotics, and deep tech.

We partner with B2B companies at the inflection point from startup to expansion, providing life-cycle capital and a value-add platform to help entrepreneurs build enduring, great growth companies.

One of Japan's most active VC firms and the venture capital arm of SBI Holdings, managing JPY 841.4 billion in cumulative fund commitments. Focused on concentrated investments in growth sectors including AI/blockchain, fintech, biotech/life sciences, and clean energy globally. Mission to cultivate key industries for the 21st century, serving as Japan's bridge to global technology ecosystems.

Material science and deep tech innovations drive outsized returns while solving urgent human problems. We back inception-stage founders turning lab breakthroughs into commercial products that make the world cleaner, more productive, and healthier.

Madrona invests in people and ideas for the long run — backing visionary founders building transformational technology companies, with deep focus on applied AI across domain-specific applications, AI infrastructure, developer tools, enterprise software, and AI-enabled biotech. The firm serves as an active, full-stack partner providing capital plus recruiting, business development, and customer introductions.

Backs globally ambitious technology companies from pre-seed and seed through selected growth rounds using specialist EMEA sector teams and a platform model for capital, customers, talent, follow-on investors, and operational support.

J12 backs technical founders early across two theses: Enablers (data infrastructure, developer tools, MLOps, and compute efficiency powering AI) and Applications (domain-specific AI products that reinvent mission-critical B2B workflows using predictive ML, computer vision, speech/multimodal, generative, and agentic systems).

Technology startups can address major global challenges. We back early and seed-stage IndustryTech, DeepTech, and CleanTech founders in the DACH region and US with capital plus network access, industry expertise, and strategic partnerships, using an evergreen structure with no fixed fund-life timing pressure.

The most valuable companies of our time will be the ones solving humanity's biggest problems across planetary health, human health, and economic health. We back exceptional founders building breakthrough solutions that create both financial returns and positive impact.

Achieve strong investment returns by investing in EBITDA-positive, founder-led healthcare companies that improve healthcare delivery. Apply the CEO Council Model — 34 senior healthcare operators who have personally invested $140M+ — to unlock growth through relationships, strategic insights, and hands-on value creation.

MS&AD Ventures partners with visionary entrepreneurs to create innovative solutions across insurance, financial services, healthcare, and sustainability. Backed by the 5th largest global insurance conglomerate, they bring capital plus global distribution across 47 countries. They move fast (2-week decisions), focus on partnerships over ownership, and help companies scale internationally.

We invest in technically sophisticated founding teams solving breakthrough problems in deep-tech. We believe the next generation of transformational companies will be built by scientists and engineers with deep domain expertise tackling problems at the frontier of AI, cybersecurity, quantum, robotics, space, synthetic biology, and bioengineering. We provide patient capital and technical partnership to help these teams achieve escape velocity.

The $12 trillion food and agriculture industries still rely on centuries-old methods. We back disruptive science and technology to modernize the food system—from biotech and sensors to automation and software—to feed 10 billion people by 2050 while preserving nature and nurturing humankind.

Partner with elite founders building transformational technologies that create lasting economic and societal value. Focus on Smart Enterprise across five sectors: Logistics, Life Sciences, Healthcare, IT Infrastructure, and Government/Defense. Invest in platforms that enable human experts to solve non-linear problems through data integration and network effects.

Entourage backs and builds early-stage B2B SaaS and software companies, combining VC capital with venture studio and founder-operator support from zero to one and beyond.

We back exceptional Nordic-based founders from seed to Series A and beyond, gravitating toward category winners riding underlying macro trends such as transparency and user-generated content. We are Denmark's largest fintech investor and a hands-on partner all the way to exit.

Back European technical founders building globally ambitious deeptech and critical technology companies at pre-seed and seed, with concentrated first-check conviction and Paris/San Francisco/Berlin support.

Women-led companies outperform male-led peers financially while using less capital. True Wealth Ventures combines gender-lens investing with impact focus, exclusively backing women-led companies improving environmental and/or human health. This unlocks superior returns while creating measurable social impact.

Backing good ideas with capital and competence - combining financial backing with active ownership, extensive networks and experienced operating support to be founders' first VC check from concept through Series A.

Back ambitious 'go-all-in' founders building defensible B2B software at pre-seed and seed, and support them intensively through the journey to Series A. Focus on AI, infrastructure, health, TechBio, open source, and marketplaces.

We help bold, creative, and humble founders build great companies by providing hands-on operational support, strategic guidance, and valuable ecosystem connections. We specialize in fintech, insurtech, digital health, and enterprise software where we can add deep value beyond capital.

Mission-driven companies solve big problems at scale while building durable competitive advantages. We back founders leveraging science & technology to build the Better Economy where people and planet thrive.

Mubadala partners with world-class companies and institutions to drive transformational growth across strategic sectors and geographies. We believe in long-term value creation through patient capital, operational expertise, and global partnerships aligned with Abu Dhabi's economic diversification.

Independent global investment platform backing capital-efficient, high-growth technology companies across Europe and North America. Multi-stage, multi-strategy approach from venture to pre-IPO. Transatlantic local teams provide unique advantage in bridging European and US growth.

Technical founders with data and technology advantages can build transformational businesses that redefine industries. We partner with experienced founders who combine technical depth with operational excellence and benefit from access to an elite network of Fortune 1000 executives and technical experts.

Bringing applied AI to legacy, historically under-digitized industries — healthcare operations, supply chain, insurance, and compliance — by combining venture capital with in-house product, engineering, and AI build-out (studio model), early-stage checks (Ventures), and control-stake modernization buyouts (Propel).

India is at a historic convergence of consumer install base, digital infrastructure (Aadhaar/UPI/Jan Dhan), quality talent, and enterprise market growth. 3one4 backs mission-driven founders building pre-consensus transformative companies for the new Indian economy with deep operational involvement and research-led conviction.

K5 Global backs category-defining companies from inception to IPO. The firm leverages exceptional networks across media, entertainment, politics, finance, and technology to provide strategic value beyond capital. We believe the best companies are built by founders who can access world-class talent, capital, and strategic relationships.

Backing outlier founders with global ambition building differentiated products in big markets, with a high helpfulness-to-cheque-size ratio rather than leading with capital size.

By 2050 the world needs to remove 5-10 billion tonnes of CO2e per year, a ~4,000x expansion of current carbon removal capacity. Counteract backs founders across every CDR pathway (DAC, mineralization, biomass, ocean, soil, MRV) rather than betting on one technology, prioritizing catalytic scale, novel science, self-sustaining economics, and regenerative co-benefits.

Venture's five-to-ten-year fund structure forces funds to sell before generational companies reach greatness. Timeless is structured to remain on the cap table for as long as greatness takes, backing founders whose work is built to outlast them.

Removing noise to see the signal: thematic, top-down research into structural demographic, technological, and policy shifts (Mega Trends), paired with founders who have true vitality. Signal Strength = Mega Trend x Founder Vitality.

We invest in early-stage Polish deep tech startups with a clear technological edge—solving hard problems through software-driven or hardware-enabled solutions. Defensible technology, early validation, and resilient founders are non-negotiables. A deeptech project without real customers becomes a research project.

Anterra backs companies that make the food system safer, more sustainable, and more resilient by combining biotechnology and digital solutions across the full value chain.

Frontier-tech venture capital backing technical founders building hard-to-replicate engineering and science breakthroughs across defense & aerospace, space, energy, semiconductors, manufacturing/IoT/robotics, advanced materials, water & agriculture, and biotech. Conviction over consensus, substance over story.

We back founders venturing beyond to build transformational companies that create positive, enduring change. Applied AI and global resilience are fundamental forces reshaping industries.

Wave Ventures backs Europe's most exceptional Gen Z founders at the earliest stage — angel and pre-seed — in the Nordics and Baltics. We invest before other VCs identify these founders, leveraging a rotating team of top university students embedded in Helsinki, Stockholm, and Tallinn startup ecosystems. We believe the most impactful companies of the next generation will emerge from this region.

Backs exceptional founders in the US, Japan, and South Korea who can become category definers, providing cross-border positioning support and long-term, high-touch partnership.

Backing entrepreneurs with Italian roots and global ambitions: Italy's first founder-backed VC, investing Pre-Seed to Series A in companies with an Italian DNA, born in Italy, expanding into Italy, or founded by Italians anywhere in the world.

Capital is a commodity, connections are currency. We back early-stage B2B founders with capital plus a network of 1,500+ venture partners, top founders, and innovation executives, and stay hands-on from first check through growth.

World-class founders at their earliest stages matter more than the stage of the business itself. We back sector-agnostic, high-ambition founders from pre-product through early revenue with candid advice, hands-on support, and a network of 1,200+ operators.

TheGP deploys experienced builders alongside capital to help founders achieve product-market fit faster. The firm's 25+ full-time builders—engineers, recruiters, designers, sales leaders—embed in portfolio companies for an average of nine months, earning equity grants tied to milestone delivery. This 'sweat equity' model creates deeper alignment than capital-only VC and is applied across Formation ($1-5M) and Breakout ($5-15M+) stages.